Biogen Inc BIIB reported its third-quarter financial results on Wednesday morning, beating the Street’s expectations. Management announced it will be reducing its workforce by 11 percent.
Biogen's earnings came in at $4.48 per share, on revenue of $2.778 billion, ahead of the Street’s consensus estimate of $3.83 per share and $2.663 billion. Management raised 2015 full year guidance and announced a corporate restructuring that will result in an 11 percent reduction in the company’s workforce.
The company announced the first patient enrollment for Phase 3 studies of aducanumab for Alzheimer’s disease, an “agreement to license Mitsubishi Tanabe Pharma’s Phase 3 ready molecule for autoimmune diseases,” and improved sales for its multiple sclerosis drug Tecfidera.
Management also publicized results of a Phase 3 trial for Natalizumab, which did not meet primary and secondary endpoints.
Despite this last piece of not-so-good news, the stock rallied and traded recently at $277.46, up more than 4.3 percent on the day.
Disclosure: Javier Hasse holds no positions in any of the securities mentioned above.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.